Global R&D Pipeline
My Favorite
Hot Targets:
IL12
Back
Total number of drugs
159
Phase II and later clinical stages
11.9%
Involving companies
222
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PF-07261271 | PF-07261271 | Bispecific antibody | Immune System Diseases Digestive System Disorders | IL-12p40 inhibitors TL1A inhibitors | Pfizer Inc. | Pfizer Inc. | Phase 1 | - | - | - | - | - | - | - | - | - | PF-07261271 | - | - | detail > | |
| MVR-C5252 | MVR-C5252 | Oncolytic virus | Neoplasms Nervous System Diseases Other Diseases | IL-12 inhibitors PD-1 inhibitors | Shenzhen Yinuowei Medical Technology Co., Ltd. | Shenzhen Yinuowei Medical Technology Co., Ltd. China Resources Biopharmaceutical Co., Ltd. | Phase 1 | IND Approval | - | - | - | Orphan Drug（United States） | - | - | - | - | MVR-C5252 | - | - | detail > | |
| JCAR-020 | JCAR-020 | Autologous CAR-T | Neoplasms Endocrinology and Metabolic Disease Urogenital Diseases | IL-12 inhibitors MUC16 inhibitors | Memorial Sloan Kettering Cancer Center | Memorial Sloan Kettering Cancer Center | Phase 1 | - | - | - | - | - | - | - | - | - | JCAR-020 | - | - | detail > | |
| Ad5-yCD/mutTKSR39rep-hIL12 | Ad5-yCD/mutTKSR39rep-hIL12 | Oncolytic virus | Neoplasms Nervous System Diseases Urogenital Diseases Other Diseases | IL-12 modulators thymidine kinase modulators | Henry Ford Health System | Henry Ford Health System | Phase 1 | - | - | - | - | - | - | - | - | - | Ad5-yCD/mutTKSR39rep-hIL12 | - | - | detail > | |
| CLN-617 | CLN-617 | Fusion protein | Neoplasms Skin and Musculoskeletal Diseases | IL-12 replacements IL-2 replacements | Cullinan Oncology LLC | Cullinan Oncology LLC | Phase 1 | - | - | - | - | - | - | - | - | - | CLN-617 | - | - | detail > | |
| Ad-TD-nslL12 | Ad-TD-nslL12 | Oncolytic virus | Neoplasms Nervous System Diseases Other Diseases Digestive System Disorders Endocrinology and Metabolic Disease Urogenital Diseases | IL-12 modulators | Capital University of Medical Sciences | Zhengzhou University Capital University of Medical Sciences | Phase 1 | Phase 1 | - | - | - | - | - | - | - | - | Ad-TD-nslL12 | - | - | detail > | |
| JCXH-212 | JCXH-212 | Therapeutic vaccine saRNA vaccine | Neoplasms Nervous System Diseases Respiratory Diseases | IL-12 modulators | Jiachen Xihai (Hangzhou) Biotechnology Co., Ltd. | Beijing Institute for Cancer Research Jiachen Xihai (Hangzhou) Biotechnology Co., Ltd. | Phase 1 | Phase 1 | - | - | - | - | - | - | - | - | JCXH-212 | - | - | detail > | |
| DF6002 | DF6002 | Fc fusion protein | Neoplasms Respiratory Diseases Skin and Musculoskeletal Diseases | IL-12 replacements Immunostimulants | Dragonfly Therapeutics, Inc. | Dragonfly Therapeutics, Inc. | Phase 1 | - | - | - | - | - | - | - | - | - | DF6002 | - | - | detail > | |
| OPB-101 | OPB-101 | CAR-T | Neoplasms Endocrinology and Metabolic Disease Urogenital Diseases | CD8 modulators IL-12 stimulants IL-15 modulators MSLN inhibitors | Outpace Bio, Inc. | Outpace Bio, Inc. | Phase 1 | - | - | - | - | - | - | - | - | - | OPB-101 | - | - | detail > | |
| JEN-101 | JEN-101 | Interleukins | Neoplasms Skin and Musculoskeletal Diseases | IL-12 stimulants | University of Illinois At UrbanaChampaign Ankyra Therapeutics, Inc. | University of Illinois At UrbanaChampaign Ankyra Therapeutics, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | JEN-101 | - | - | detail > |
Total 159 data
1
2
3
4
5
6
...
15
16
